The increasing number of public genomic datasets and customer demand for integrated database have been driving Omicsoft's Land database development. In just a few short years, our flagship Land, OncoLand, has been an overwhelming success and is now being used by most of our pharma and biotech customers. Encouraged by our OncoLand success, we are in the process of bringing a series of DiseaseLand products to our customers, including the recently released ImmunoLand and the upcoming MetabolicLand.
MetabolicLand is designed for metabolic disease data, for example, diabetes and obesity, as well as cardiovascular diseases. By the end of 2015, MetabolicLand will be tested and used by a few of our prestigious pharmaceutical clients.
We will have three distinct Land products covering all disease areas:
1. OncoLand (Oncology)
2. ImmunoLand (immune related diseases and neurological diseases)
3. MetabolicLand (Metabolic and Cardiovascular diseases)
We will do our best to fit all remaining diseases that we have not yet covered into these three categories, as least as it related to genomic data.
Before its release, we would like to show you a few snapshots of our MetabolicLand. Schedule a meeting with us through firstname.lastname@example.org if you are interested in metabolic disease genomic and clinical data. Also, talk to us if you have public or private datasets of interest. We would love to customize the Land for your research needs.
Together, let Omicsoft help improve your metabolic and cardiovascular disease research and drug development.